These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 38277059)

  • 21. The Relationship Between the Molecular Phenotypes of Brain Gliomas and the Imaging Features and Sensitivity of Radiotherapy and Chemotherapy.
    Huang YR; Fan HQ; Kuang YY; Wang P; Lu S
    Clin Oncol (R Coll Radiol); 2024 Sep; 36(9):541-551. PubMed ID: 38821723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
    Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
    Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imaging Correlates of Adult Glioma Genotypes.
    Smits M; van den Bent MJ
    Radiology; 2017 Aug; 284(2):316-331. PubMed ID: 28723281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting Genotype and Survival in Glioma Using Standard Clinical MR Imaging Apparent Diffusion Coefficient Images: A Pilot Study from The Cancer Genome Atlas.
    Wu CC; Jain R; Radmanesh A; Poisson LM; Guo WY; Zagzag D; Snuderl M; Placantonakis DG; Golfinos J; Chi AS
    AJNR Am J Neuroradiol; 2018 Oct; 39(10):1814-1820. PubMed ID: 30190259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radiomics in gliomas: A promising assistance 
for glioma clinical research.
    Leng Y; Wang X; Liao W; Cao Y
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Apr; 43(4):354-359. PubMed ID: 29774870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. World Health Organization Grade II/III Glioma Molecular Status: Prediction by MRI Morphologic Features and Apparent Diffusion Coefficient.
    Maynard J; Okuchi S; Wastling S; Busaidi AA; Almossawi O; Mbatha W; Brandner S; Jaunmuktane Z; Koc AM; Mancini L; Jäger R; Thust S
    Radiology; 2020 Jul; 296(1):111-121. PubMed ID: 32315266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adult IDH wild-type lower-grade gliomas should be further stratified.
    Aibaidula A; Chan AK; Shi Z; Li Y; Zhang R; Yang R; Li KK; Chung NY; Yao Y; Zhou L; Wu J; Chen H; Ng HK
    Neuro Oncol; 2017 Oct; 19(10):1327-1337. PubMed ID: 28575485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multimodel habitats constructed by perfusion and/or diffusion MRI predict isocitrate dehydrogenase mutation status and prognosis in high-grade gliomas.
    Liu J; Cong C; Zhang J; Qiao J; Guo H; Wu H; Sang Z; Kang H; Fang J; Zhang W
    Clin Radiol; 2024 Jan; 79(1):e127-e136. PubMed ID: 37923627
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Laboratory Testing Practices in Diffuse Gliomas Prior to Publication of 2021 World Health Organization Classification of Central Nervous System Tumors.
    Ramkissoon SH; Fernandes H; Lopez-Terrada DH; Hameed MR; Trembath DG; Bridge JA; Lindeman NI; Souers RJ; Vasalos P; Brat DJ; Moncur JT
    Arch Pathol Lab Med; 2022 May; 147(5):518-524. PubMed ID: 35878398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. WHO CNS5 2021 includes specific mutations in gliomas that can be identified with MRI quantitative biomarkers.
    García-Lezama M; Carrillo-Ruiz JD; Moreno-Jiménez S; Roldán-Valadez E
    Gac Med Mex; 2023; 159(2):161-168. PubMed ID: 37094238
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.
    Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F
    World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The 2021 WHO Classification for Gliomas and Implications on Imaging Diagnosis: Part 3-Summary of Imaging Findings on Glioneuronal and Neuronal Tumors.
    Park YW; Vollmuth P; Foltyn-Dumitru M; Sahm F; Choi KS; Park JE; Ahn SS; Chang JH; Kim SH
    J Magn Reson Imaging; 2023 Dec; 58(6):1680-1702. PubMed ID: 37715567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Updates on the WHO diagnosis of IDH-mutant glioma.
    Reuss DE
    J Neurooncol; 2023 May; 162(3):461-469. PubMed ID: 36717507
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.
    Weller M; Weber RG; Willscher E; Riehmer V; Hentschel B; Kreuz M; Felsberg J; Beyer U; Löffler-Wirth H; Kaulich K; Steinbach JP; Hartmann C; Gramatzki D; Schramm J; Westphal M; Schackert G; Simon M; Martens T; Boström J; Hagel C; Sabel M; Krex D; Tonn JC; Wick W; Noell S; Schlegel U; Radlwimmer B; Pietsch T; Loeffler M; von Deimling A; Binder H; Reifenberger G
    Acta Neuropathol; 2015 May; 129(5):679-93. PubMed ID: 25783747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular classification of patients with grade II/III glioma using quantitative MRI characteristics.
    Bahrami N; Hartman SJ; Chang YH; Delfanti R; White NS; Karunamuni R; Seibert TM; Dale AM; Hattangadi-Gluth JA; Piccioni D; Farid N; McDonald CR
    J Neurooncol; 2018 Sep; 139(3):633-642. PubMed ID: 29860714
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imaging features associated with H3 K27-altered and H3 G34-mutant gliomas: a narrative systematic review.
    Lasocki A; Abdalla G; Chow G; Thust SC
    Cancer Imaging; 2022 Nov; 22(1):63. PubMed ID: 36397143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic and Predictive Biomarkers in Gliomas.
    Śledzińska P; Bebyn MG; Furtak J; Kowalewski J; Lewandowska MA
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic performance of gliomas grading and IDH status decoding A comparison between 3D amide proton transfer APT and four diffusion-weighted MRI models.
    Guo H; Liu J; Hu J; Zhang H; Zhao W; Gao M; Zhang Y; Yang G; Cui Y
    J Magn Reson Imaging; 2022 Dec; 56(6):1834-1844. PubMed ID: 35488516
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relevance of calcification and contrast enhancement pattern for molecular diagnosis and survival prediction of gliomas based on the 2016 World Health Organization Classification.
    Michiwaki Y; Hata N; Mizoguchi M; Hiwatashi A; Kuga D; Hatae R; Akagi Y; Amemiya T; Fujioka Y; Togao O; Suzuki SO; Yoshimoto K; Iwaki T; Iihara K
    Clin Neurol Neurosurg; 2019 Dec; 187():105556. PubMed ID: 31639630
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association between glioma susceptibility loci and tumour pathology defines specific molecular etiologies.
    Di Stefano AL; Enciso-Mora V; Marie Y; Desestret V; Labussière M; Boisselier B; Mokhtari K; Idbaih A; Hoang-Xuan K; Delattre JY; Houlston RS; Sanson M
    Neuro Oncol; 2013 May; 15(5):542-7. PubMed ID: 23161787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.